{"id":3168,"date":"2018-05-04T16:14:35","date_gmt":"2018-05-04T14:14:35","guid":{"rendered":"http:\/\/www.igmm.cnrs.fr\/?p=3168"},"modified":"2018-05-04T16:14:45","modified_gmt":"2018-05-04T14:14:45","slug":"targeting-sumo-to-improve-the-efficiency-of-differentiation-therapies-in-acute-myeloid-leukemias","status":"publish","type":"post","link":"https:\/\/www.igmm.cnrs.fr\/en\/targeting-sumo-to-improve-the-efficiency-of-differentiation-therapies-in-acute-myeloid-leukemias\/","title":{"rendered":"Targeting SUMO to improve the efficiency of differentiation therapies in Acute Myeloid Leukemias"},"content":{"rendered":"<p>Acute Myeloid Leukemias (AML) are very aggressive hematological malignancies, which treatment is mostly based on intensive chemotherapies. This treatment has not significantly changed in the past 40 years and is characterized by a high relapse rate. Differentiation therapies, in particular those using all-trans retinoic acid (ATRA) are an alternative to chemotherapies. They aim at restoring the differentiation of AML cells and induce a cell cycle arrest and their death. However, they are only efficient in Acute Promylocytic Leukemis, a minor subtype of AML. The work by Hayeon Baik et al, from the Oncogenesis and Immunotherapy team, and published in Cancer Research, has shown that SUMOylation, a post-translational modification of the ubiquitin family, repress ATRA target genes, in particular those involved in differentiation, cell cycle arrest and apoptosis. Pharmacological or genetic inhibition of SUMOylation reactivates these genes and facilitates the differentiation and death of leukemic cells in various models, including patient cells. Altogether this work opens new therapeutic perspectives in the treatment of AML, a very poor prognosis cancer.<\/p>\n<figure id=\"attachment_3167\" aria-describedby=\"caption-attachment-3167\" style=\"width: 450px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-3167 size-medium\" src=\"http:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2018\/05\/mpl-slide-v1-450x372.jpg\" alt=\"\" width=\"450\" height=\"372\" srcset=\"https:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2018\/05\/mpl-slide-v1-450x372.jpg 450w, https:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2018\/05\/mpl-slide-v1.jpg 700w\" sizes=\"auto, (max-width: 450px) 100vw, 450px\" \/><figcaption id=\"caption-attachment-3167\" class=\"wp-caption-text\">Figure: cellules de patients trait\u00e9es in vitro avec l\u2019ATRA +\/- 2-D08 (inhibiteur de SUMOylation)<\/figcaption><\/figure>\n<p><strong>To know more<\/strong><\/p>\n<p>Baik H, Boulanger M, Hosseini M, Kowalczyk J, Zaghdoudi S, Salem T, Sarry JE, Hicheri Y, Cartron G, Piechaczyk M, Bossis G.<\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Targeting+the+SUMO+pathway+primes+all-trans+retinoic\">Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of non-promyelocytic acute myeloid leukemias. <\/a><\/p>\n<p><a href=\"http:\/\/cancerres.aacrjournals.org\/content\/early\/2018\/02\/27\/0008-5472.CAN-17-3361\">Cancer Res<\/a>. 2018 Feb 27. pii: canres.3361.2017. <a href=\"http:\/\/cancerres.aacrjournals.org\/content\/early\/2018\/02\/27\/0008-5472.CAN-17-3361\">doi: 10.1158\/0008-5472.CAN-17-3361<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acute Myeloid Leukemias (AML) are very aggressive hematological malignancies, which treatment is mostly based on intensive chemotherapies. This treatment has not significantly changed in the past 40 years and is characterized by a high relapse rate. Differentiation therapies, in particular those using all-trans retinoic acid (ATRA) are an alternative to chemotherapies. They aim at restoring the differentiation of AML cells &hellip; <a href=\"https:\/\/www.igmm.cnrs.fr\/en\/targeting-sumo-to-improve-the-efficiency-of-differentiation-therapies-in-acute-myeloid-leukemias\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Targeting SUMO to improve the efficiency of differentiation therapies in Acute Myeloid Leukemias<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":3167,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16],"tags":[],"class_list":["post-3168","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-news","category-science-en"],"_links":{"self":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/3168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/comments?post=3168"}],"version-history":[{"count":1,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/3168\/revisions"}],"predecessor-version":[{"id":3172,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/3168\/revisions\/3172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media\/3167"}],"wp:attachment":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media?parent=3168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/categories?post=3168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/tags?post=3168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}